louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06843057: Kinesiotaping Along with Mulligan's Mobilization with Movement in Adhesive Capsulitis
Official title: Effectiveness of Kinesiotaping Along with Mulligan's Mobilization with Movement on Improving Pain and Function in Patients with Adhesive Capsulitis of Shoulder: a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Adhesive Capsulitis
Keywords: Rehabilitation
Manual Therapy
Exercise Therapy
Shoulder Pain
Lead sponsor: King Saud University
Sponsor class: OTHER
First posted: 2025-02-24
Enrollment: 30
Sex: ALL
Minimum age (years): 40
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Two Parallel Arms Experimental Design
Primary purpose: TREATMENT

Brief summary: The study aimed to evaluate the effectiveness of combining Kinesiotaping with Mulligan's mobilization with movement in treating shoulder adhesive capsulitis. Thirty patients participated in a randomized control trial, divided equally into an experimental group and a control group. The experimental group received Kinesiotaping, Mulligan's mobilization with movement, and conventional physiotherapy, while the control group received only Mulligan's mobilization with movement and conventional physiotherapy. Pain, range of motion, and functional outcomes were measured using a visual analogue scale, goniometer, and the Shoulder Pain and Disability Index (SPADI) questionnaire.


Eligibility criteria: Inclusion Criteria:

* Primary adhesive capsulitis,
* Controlled diabetes mellitus,
* Restriction of movements in capsular pattern,
* Shoulder pain for more than one month.

Exclusion Criteria:

* Secondary adhesive capsulitis,
* Cancer,
* Bilateral adhesive capsulitis,
* Skin infections in the shoulder region,
* Shoulder joint infections,
* Wounds or ulcers in the shoulder region,
* Hypersensitivity to tape,
* Recent shoulder dislocation,
* Recent shoulder fractures.

Primary outcomes:
measure: Visual Analogue Scale
timeFrame: From enrollment to the end of treatment at 4 weeks
measure: Range of motion
timeFrame: From enrollment to the end of treatment at 4 weeks
measure: Shoulder Pain and Disability Index
timeFrame: From enrollment to the end of treatment at 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Calicut
country: India
facility: AWH Special College
state: Kerala
Study officials:
affiliation: King Saud University
name: Masood Khan, MPTh
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00822757: Safety and Immunogenicity Study of V710 Lyophilized Formulation (V710-004)
Official title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of a Single Dose of the Lyophilized Formulation of Merck Staphylococcus Aureus Vaccine (V710) in Healthy Adults
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Keywords: study in healthy subjects
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2009-01-14
Enrollment: 51
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study is being performed to evaluate a single 60 Mcg dose of lyophilized formulation of Merck Staphylococcus aureus vaccine (V710) in healthy subjects. This study is intended to provide necessary safety and immunogenicity data for the lyophilized formulation of V710 prior to its subsequent evaluation in patients at risk for developing serious S. aureus infections.


Eligibility criteria: Inclusion Criteria:

* 18 to 80 years of age
* Good physical health based upon medical history and physical examination
* Willing and able to participate in the entire study duration
* Female subject with a negative urine pregnancy test immediately prior to study vaccination

Exclusion Criteria:

* Chronic skin infections or a chronic skin condition (e.g. psoriasis)
* Serious S. aureus infection in the last 12 months
* Allergy to aluminum-containing substance taken in the body or to any other vaccine component
* Oral temperature equal to or greater than 100.4ºF (38.0ºC), within the past 2 days
* Participation in a prior V710 vaccine clinical study
* Participation in any other clinical study in the past 4 weeks, or during the 3-month study duration

Primary outcomes:
measure: Geometric Mean Fold-rise (GMFR) After the Administration of the Lyophilized Formulation of V710 (60 mcg).
timeFrame: Prevaccination to 14 days postvaccination
Secondary outcomes:
Other outcomes:
measure: GMFR by Age
timeFrame: Prevaccination to 14 days postvaccination
measure: GMFR in Antibody Concentration From Baseline
timeFrame: Prevaccination to Days 10, 14, 28, and 84 postvaccination
Locations:
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Monitor
role: STUDY_DIRECTOR
References:
citation: Harro CD, Betts RF, Hartzel JS, Onorato MT, Lipka J, Smugar SS, Kartsonis NA. The immunogenicity and safety of different formulations of a novel Staphylococcus aureus vaccine (V710): results of two Phase I studies. Vaccine. 2012 Feb 21;30(9):1729-36. doi: 10.1016/j.vaccine.2011.12.045. Epub 2011 Dec 20.
Clinical trial NCT04660357: Osteoarthritis, Balance, and Fear of Falling
Official title: Do Activity-Specific Balance Confidence and Fear of Fall Affect Autonomy and Social Participation in Individuals With Knee Osteoarthritis Above 65 Years Old?
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Osteoarthritis
Lead sponsor: Hacettepe University
Sponsor class: OTHER
First posted: 2020-12-09
Enrollment: 80
Sex: ALL
Minimum age (years): 65
Maximum age (years): 90
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: * 65 years old
* Diagnosed with knee osteoarthritis according to ACR diagnostic criteria

Brief summary: Osteoarthritis (OA) is a progressive and irreversible degenerative joint disease characterized by marginal bone hypertrophy, erosion, and subchondral sclerosis in the articular cartilage.It has been determined that being of advanced age and joint involvement due to osteoarthritis are a risk factor for addiction in activities and this increases the individual's self-care ability and dependency in daily living activities.Older individuals with knee osteoarthritis may be at risk of falling.This study was planned to examine the relationship between activity-specific balance confidence and fear of falling, autonomy and social participation in individuals with knee osteoarthritis over 65 years of age.

Detailed description: Osteoarthritis (OA) is a progressive and irreversible degenerative joint disease characterized by marginal bone hypertrophy, erosion, and subchondral sclerosis in the articular cartilage.It has been determined that being of advanced age and joint involvement due to osteoarthritis are a risk factor for addiction in activities and this increases the individual's self-care ability and dependency in daily living activities.Older individuals with knee osteoarthritis may be at risk of falling.Considering the relationship between the concepts of osteoarthritis and old age with the common concepts of daily life activity problems, falling, loss of autonomy and affecting social participation; this study was planned to examine the relationship between activity-specific balance confidence and fear of falling, autonomy and social participation in individuals with knee osteoarthritis over 65 years of age.

Eligibility criteria: Inclusion Criteria:

* 65 years old
* Diagnosed with knee osteoarthritis according to ACR diagnostic criteria

Exclusion Criteria:

Not having enough cooperation

Primary outcomes:
measure: WOMAC, The Activities-specific Balance Confidence Scale, Falls Efficacy Scale, The functional autonomy measurement system, Community Integration Questionnaire, Berg Balance Scale
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Edirne
country: Turkey
facility: Özgü İnal
state: Merkez
Study officials:
affiliation: Trakya University
name: Özgü İnal
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05012657: Validation of Point Partial User Needs With Partial Finger Amputees
Official title: Validation of Point Partial User Needs With Partial Finger Amputees
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Amputation; Traumatic, Hand
Lead sponsor: Point Designs
Sponsor class: INDUSTRY
Collaborators: name: University of Colorado, Denver
First posted: 2021-08-19
Enrollment: 5
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DEVICE_FEASIBILITY

Brief summary: The objective of the device feasibility study will be to validate the user needs of the Point Partial system. This study will be a single group intervention model where one group of 5 partial finger amputees will be asked to perform several tasks. Successful completion of a task results in a fulfilled user need. Failure to complete a task results in an unfulfilled user need.


Eligibility criteria: Inclusion Criteria:

* Partial finger amputees with partial absence of index and/or middle fingers and presence of thumb. Additional finger loss is acceptable if all other criterion are met.
* Fluent in English
* Individuals aged 18 or greater
* Patients may present with either fused or mobile MCP joints.

Exclusion Criteria:

* Significant cognitive deficits as determined upon clinical evaluation
* Significant neurological deficits as determined upon clinical evaluation
* Significant physical deficits of the residual limb impacting full participation in the study as determined upon clinical evaluation
* Uncontrolled pain or phantom pain impacting full participation in the study as determined upon OT evaluation
* Serious uncontrolled medical problems as judged by the project therapist.

Primary outcomes:
measure: VAL-1: System Comfort Validation Test
timeFrame: Day 1 (8 hours)
measure: VAL-2: Unilateral Function Validation Test
timeFrame: Day 1 (10 minutes)
measure: VAL-3.1: System Robustness Validation Test With 25 lb Bag
timeFrame: Day 1 (10 minutes)
measure: VAL-3.2: Robustness Validation Test With Hammer
timeFrame: Day 1 (10 minutes)
measure: VAL-4: Object Release Validation Test
timeFrame: Day 1 (10 minutes)
measure: VAL-5: Position Function Validation Test
timeFrame: Day 1 (10 minutes)
measure: VAL-6: Extension Function Validation Test
timeFrame: Day 1 (10 minutes)
measure: VAL-7: Grip Functions Validation Test
timeFrame: Day 1 (10 minutes)
measure: VAL-8: Fine Motor Function Validation Test
timeFrame: Day 1 (10 minutes)
measure: VAL-9: Overall Function & Robustness Validation Test
timeFrame: Day 1 (8 hours)
Secondary outcomes:
Other outcomes:
Locations:
city: Aurora
country: United States
facility: University of Colorado Denver | Anschutz Medical Campus
state: Colorado
city: Lafayette
country: United States
facility: Point Designs
state: Colorado
Study officials:
References:
Clinical trial NCT01393457: Cognitive Remediation for Cocaine Dependence
Official title: Cognitive-enhancing DA Medications for Cocaine Dependence
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Cocaine Dependence
Keywords: cocaine
cognition
medication
treatment
Lead sponsor: The University of Texas Health Science Center, Houston
Sponsor class: OTHER
First posted: 2011-07-13
Enrollment: 119
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate treatments designed to improve cocaine treatment success by combining medications that target cocaine-related cognitive impairments.


Eligibility criteria: Inclusion Criteria:

* meet criteria for cocaine dependence
* seeking treatment for cocaine dependence
* be in acceptable health based on medical history and physical exam

Exclusion Criteria:

* dependent on drugs other than cocaine, nicotine, marijuana
* have a medical condition contraindicating treatment with study medications
* having conditions of probation or parole requiring reports of drug use to officers of the court

Primary outcomes:
measure: Cocaine Use Based on Urine Drug Screening
timeFrame: 10 weeks
Secondary outcomes:
measure: Number of Participants Who Completed the 10 Week Trial
timeFrame: 10 weeks
Other outcomes:
Locations:
city: Houston
country: United States
facility: Behavioral and Biomedical Sciences Building
state: Texas
Study officials:
References:
citation: Suchting R, Green CE, de Dios C, Vincent J, Moeller FG, Lane SD, Schmitz JM. Citalopram for treatment of cocaine use disorder: A Bayesian drop-the-loser randomized clinical trial. Drug Alcohol Depend. 2021 Nov 1;228:109054. doi: 10.1016/j.drugalcdep.2021.109054. Epub 2021 Sep 23.
Clinical trial NCT01910857: Improving Hypertension Control
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hypertension
Lead sponsor: Medical College of Wisconsin
Sponsor class: OTHER
Collaborators: name: Progressive Community Health Center
First posted: 2013-07-30
Enrollment: 60
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: * The overall hypothesis for the project is that racial health disparities will be reduced by improving hypertension control in African Americans.
* This will be accomplished through the development, implementation, and evaluation of a cost-effective hypertension control strategy based on the involvement of a community health worker.


Eligibility criteria: Inclusion Criteria:

* African Americans with uncontrolled hypertension, followed at Progressive Community Health Centers

Primary outcomes:
measure: Change in blood pressure (mmHg)
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Milwaukee
country: United States
facility: Lisbon Avenue Health Center
state: Wisconsin
city: Milwaukee
country: United States
facility: Hillside Family Health Center
state: Wisconsin
Study officials:
References:
citation: Tully M, Kos A, Eastwood D, Kusch J, Kotchen T. Implementation of an Adjunct Strategy to Reduce Blood Pressure in Blacks with Uncontrolled Hypertension: a Pilot Project. Ethn Dis. 2015 Spring;25(2):168-74.
Clinical trial NCT06709157: Immunocompetent Versus Immunocompromised Tuberculosis (TB) Patients
Official title: Immunocompetent Versus Immunocompromised Tuberculosis (TB) Patients
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Tuberculosis
Keywords: HIV
immunocompromised
cytokines
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2024-11-29
Enrollment: 200
Sex: ALL
Minimum age (years): 16
Maximum age (years): 60
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This prospective study will be conducted on 100-200 patients with pulmonary and extra pulmonary TB attending Sohag University Hospital during the period from September 2024 to August 2025

Brief summary: Tuberculosis (TB) is caused by Mycobacterium tuberculosis and is one of the top 10 causes of mortality worldwide. It is estimated that in 2017, 10 million people were infected with TB, and 1.6 million died from the disease, including 0.3 million people with human immunodeficiency virus (HIV) infection . TB remains the primary killer of HIV-positive individuals. TB incidence is falling at about 2% per year . Airborne transmission of M. tuberculosis typically causes TB infection in both immunocompetent and immunocompromised hosts and the disease is symptomatic and contagious .

Detailed description: TB and HIV infections are strictly linked together. TB is the most common opportunistic infection and causes high morbidity rate among people living with HIV. Because of the decrease in cell-mediated immunity, HIV alters the pathogenesis of TB, thereby expressively increasing the risk of TB in HIV-positive patients and eventually leading to more severe complications and forms of TB.

Eligibility criteria: Inclusion Criteria:

* Patients with chronic chest disease

Exclusion Criteria:

* Patients with other respiratory or infectious diseases.

Primary outcomes:
measure: The Prevalance of tubercuolsis in immunocompetent patients suffereing from chronic chest problems
timeFrame: December 2024- June 2025
measure: The prevalence of tuberculosis in HIV patients
timeFrame: December 2024- June 2025
Secondary outcomes:
Other outcomes:
Locations:
city: Sohag
country: Egypt
facility: Faculty of medicine
Study officials:
affiliation: Sohag university, Faculty of medicine
name: Noha S Shafik, Lecturer
role: PRINCIPAL_INVESTIGATOR
affiliation: Sohag university, Faculty of Medicine
name: Asmaa T Mostafa, Lecturer
role: STUDY_CHAIR
affiliation: Sohag university, Faculty of Medicine
name: Ebtisam M Gad, Lecturer
role: STUDY_CHAIR
affiliation: Sohag university, Faculty of Medicine
name: Mona M Abdelrahman, Lecturer
role: STUDY_CHAIR
affiliation: Sohag university, Faculty of medicine
name: Dina H Mohamed, Lecturer
role: STUDY_CHAIR
References:
Clinical trial NCT02510157: Effect of Dexamethasone on the Action of Sugammadex
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Neuromuscular Blockade
Keywords: sugammadex
dexamethasone
neuromuscular blockade
Lead sponsor: Attikon Hospital
Sponsor class: OTHER
First posted: 2015-07-29
Enrollment: 44
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: This study aims to investigate the possible clinical effect of dexamethasone on the action of sugammadex when it is administered to reverse deep neuromuscular blockade caused by rocuronium in laparoscopic cholecystectomies.


Eligibility criteria: Inclusion Criteria:

* patients aged 18-70 years
* laparoscopic cholecystectomy
* operation \< 3 hours

Exclusion Criteria:

* age \<18 or \>70 years old
* ASA physical status \>3
* central nervous system diseases
* severe psychiatric disorders under treatment
* cognitive dysfunction
* known or suspected allergy to the administered drugs
* operations \> 3 hours
* surgical intraoperative complications-open cholecystectomy
* severe renal or liver disease
* diabetes melitus
* immunosuppressed patients
* chronic immunosuppresant therapy (corticosteroids or other drugs)
* all contraindications to corticosteroids administration
* patiens on chronic use of opioids

Primary outcomes:
measure: Time to train-of-four (TOF) ratio of 0.9 since administration of sugammadex
timeFrame: minutes after administration of sugammadex (0 to 30 minutes)
Secondary outcomes:
measure: Postoperative pain
timeFrame: 1, 6, 12, 24 hours postoperatively
measure: Postoperative nausea and vomiting
timeFrame: 1, 6, 12, 24 hours postoperatively
Other outcomes:
measure: Time from end of surgery to extubation of patient
timeFrame: minutes after administration of sugammadex (0 to 30 minutes)
Locations:
city: Athens
country: Greece
facility: 2nd Department of Anesthesiology, Attikon Hospital, 1 Rimini str.
Study officials:
References:
Clinical trial NCT04860557: Comparison of the Dual Task, Cognitive Skills and Physical Activity With Problematic Game Players and Control Subjects
Official title: Comparison of the Dual Task, Cognitive Skills and Physical Activity With Problematic Game Players and Control Subjects
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Problematic Video Gaming
Cognitive Skill
Dual Task
Physical Activity
Lead sponsor: Hasan Kalyoncu University
Sponsor class: OTHER
First posted: 2021-04-27
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: University students in Hasan Kalyoncu University

Brief summary: This study was conducted to compare the cognitive skills, dual-task and physical activity status of individuals who play problem video games and healthy individuals, and to determine how much these skills are affected. The cognitive skills of individuals with video game playing problems and the control group were evaluated with the Montreal Cognitive Assessment Test, the Trail Making Test A \& B sections, and the Stroop test. I evaluated dual tasks with 10-meter walking test (single-double task) and Time Up and Go Test (single-double task). Physical activity levels were evaluated by International Physical Active Questionnaire. The average cognitive skills, dual tasks, and physical activity levels of the individuals in both groups were compared.


Eligibility criteria: Inclusion Criteria:

* DSM V (Diagnostic and Statistical Manual of Mental Disorders, revision 5) Internet Gaming Disorder (IOOB) Diagnostic criteria: Providing 5 out of 9 items
* No communication barrier
* To volunteer to participate in research
* Be playing games at least 2 hours a day in the last year

Exclusion Criteria:

* 3 days a week to be doing any sports
* Having a chronic illness
* Psychological disease diagnosis

Primary outcomes:
measure: International Physical Activity Questionnaire (IPAQ)
timeFrame: 1 days
measure: The Exercise Benefits/Barriers Scale
timeFrame: 1 day
measure: Montreal Cognitive Assessment Test
timeFrame: 1 day
measure: Trail Making Test (TMT) A & B sections
timeFrame: 1 day
measure: Stroop Test
timeFrame: 1 day
measure: 10 meter walking test
timeFrame: 1 day
measure: Timed Up & Go (TUG) test
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Gaziantep
country: Turkey
facility: Hasan Kalyoncu Universty
state: Şahinbey
Study officials:
References:
Clinical trial NCT01939457: 400mcg Sublingual Misoprostol as First Line Treatment
Official title: Introduction of 400mcg Sublingual Misoprostol as First Line Treatment in 11 Health Posts in Three Districts in Senegal
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Incomplete Abortion
Lead sponsor: Gynuity Health Projects
Sponsor class: OTHER
First posted: 2013-09-11
Enrollment: 641
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Women presenting with incomplete abortion and eligible for treatment with misoprostol were offered 400mcg sublingual misoprostol for treatment. Based on existing literature, the study hypothesises that women can successfully be treated with misoprostol alone as first line treatment.


Eligibility criteria: Inclusion Criteria:

* uterine size less than 12 weeks lmp
* open cervical os
* current or past vaginal bleeding
* willing to provide contact information for follow-up
* over 18 or with guardian consent

Exclusion Criteria:

* suspicion of ectopic pregnancy
* intrauterine device in place
* bad general health (infection, anemia, shoc)

Primary outcomes:
measure: complete abortion
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Guediawaye
country: Senegal
facility: Guediawaye Health Center
Study officials:
affiliation: Gynuity Health Projects
name: Beverly Winikoff, MD MPH
role: PRINCIPAL_INVESTIGATOR
References:
citation: Gaye A, Diop A, Shochet T, Winikoff B. Decentralizing postabortion care in Senegal with misoprostol for incomplete abortion. Int J Gynaecol Obstet. 2014 Sep;126(3):223-6. doi: 10.1016/j.ijgo.2014.03.028. Epub 2014 May 15.